Safi Biotherapeutics
Safi Biotherapeutics Awarded a $4.7 Million Extension by U.S. DoW to Advance Manufactured Red Blood Cells Toward First Clinical Trial
Award funds the final IND-enabling work needed prior to initiating Safi's first clinical trial CAMBRIDGE, Mass., Nov. 3, 2026 — Safi Biotherapeutics,…